A Study in Subjects With Retinitis Pigmentosa
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05392179 |
Recruitment Status :
Completed
First Posted : May 26, 2022
Last Update Posted : April 18, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Retinitis Pigmentosa | Drug: ADX-2191 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa |
Actual Study Start Date : | July 14, 2022 |
Actual Primary Completion Date : | June 23, 2023 |
Actual Study Completion Date : | June 23, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: ADX-2191 Three Injections |
Drug: ADX-2191
Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16. |
Experimental: ADX-2191 Six Injections |
Drug: ADX-2191
Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16. |
- Number of participants with adverse events (AEs) [ Time Frame: 16 weeks ]Assessing the safety of ADX-2191 in patients with retinitis pigmentosa from AE collection
- Change in visual acuity [ Time Frame: 16 weeks ]Assessing the change in visual acuity in patients with retinitis pigmentosa treated with ADX-2191 using the Early Treatment Diabetic Retinopathy (ETDRS) chart.
- Central retinal sensitivity [ Time Frame: 16 weeks ]Assessing the central retinal sensitivity in patients using microperimetry, measured in decibels
- Change in dark-adapted retinal sensitivity [ Time Frame: 16 weeks ]Assessing the change in dark-adapted retinal sensitivity in patients using dark adapted chromatic perimetry, measured in decibels
- Assessment for change in central subfield foveal thickness and ellipsoid zone area/width [ Time Frame: 16 weeks ]Assessing the change in central subfield foveal thickness and ellipsoid zone area/width in patients using Spectral-Domain Optical Coherence Tomography (SD-OCT) as measured in square millimeters
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Up to 8 adult patients age 18 or older
- Diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including P23H
- Impairment on Visual Field as determined by perimetry
Exclusion Criteria:
- Age < 18 years
- Pregnant
- Previous inflammatory/infectious events involving the eyes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05392179
United States, North Carolina | |
Duke Eye Center | |
Durham, North Carolina, United States, 27710 |
Responsible Party: | Aldeyra Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT05392179 |
Other Study ID Numbers: |
ADX-2191-RP-001 |
First Posted: | May 26, 2022 Key Record Dates |
Last Update Posted: | April 18, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
ADX-2191 Methotrexate Retinitis Pigmentosa Rhodopsin Mutation P23H |
Retinitis Retinitis Pigmentosa Retinal Diseases Eye Diseases |
Eye Diseases, Hereditary Retinal Dystrophies Retinal Degeneration Genetic Diseases, Inborn |